A phase II study of fluorodopan in the treatment of advanced colorectal cancer.
In an early phase II study, fluorodopan (5-(2'-fluoroethyl-2'-chloroethyl)-amino-6-methyl uracil) was given to 17 patients with advanced colorectal cancer previously treated with multiple agents. Side effects included mild nausea and vomiting in 14 patients, platelet counts of less than 50,000/microliter in four patients, and wbc counts of less than 2000/microliter in two patients. Partial remission lasting 9 weeks was achieved in one patient, and stable disease with a mean duration of 7.1 weeks was achieved in ten patients. Given in this setting fluorodopan does not appear to have a significant effect in terms of regression of tumor or prolongation of survival.
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D003110:Colonic Neoplasms / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008297:Male; D012004:Rectal Neoplasms / Q000188:drug therapy*; D014499:Uracil Mustard / Q000031:analogs & derivatives* / Q000627:therapeutic use
D000970:Antineoplastic Agents; C001234:fluorodopan; D014499:Uracil Mustard